Anavex Life Sciences Corp.
LSE: 0HFR.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Christopher U. Missling
- Employees
- 42
- Headquarters
- New York City, United States
- IPO year
- 2018
- Market cap
- $299.3M
- Website
- https://www.anavex.com
Loading 0HFR…
Loading profile data…Frequently asked questions about 0HFR
What does Anavex Life Sciences Corp. (0HFR.L) do?
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
Where does 0HFR.L trade?
Anavex Life Sciences Corp. (0HFR.L) trades on the London Stock Exchange.
What sector is 0HFR.L in?
Anavex Life Sciences Corp. (0HFR.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Anavex Life Sciences Corp.?
Christopher U. Missling is the chief executive officer of Anavex Life Sciences Corp. (0HFR.L).
Where is Anavex Life Sciences Corp. headquartered?
Anavex Life Sciences Corp. is headquartered in United States.
Does 0HFR.L pay a dividend?
Anavex Life Sciences Corp. (0HFR.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HFR.L go public?
Anavex Life Sciences Corp. (0HFR.L) completed its initial public offering in 2018.